leisure time -WSS

leisure time

author：knowledge 2025-10-02 18:47:56 - browse：11157

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： New weight loss drugs vying to be the next Wegovy or Mounjaro

knowledge

WSS

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

FDA panel endorses Alnylam’s heart drug — after picking it apart

IRA could hurt research into orphan drugs for rare diseases

Cheap, fast test for Zika and dengue could cost just $1

The system is set up to fail children with medical complexity

The system is set up to fail children with medical complexity

leisure time

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

leisure time

In age of alternative facts, a scholarly course on calling out crap

Readers discuss the intersection of pregnancy and addiction

At least 13 dead in Texas as scorching temps continue

White House touts steps to stem shortages of cancer treatments

New air purifier tech could be key to improving indoor air quality

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Bright Health sells Medicare Advantage business to Molina

WATCH: Why do bright lights make us see spots?

After affirmative action ruling, medical educators look to 'holistic review'

Long Covid needs a new name — and a new frame

leisure time

ALS patient reclaims some autonomy thanks to wearable 'robot'

Readers discuss the intersection of pregnancy and addiction

Generate Biomedicines machine learning biotech raises $273M

Stephen Quake on the Chan Zuckerberg quest to conquer disease

White House touts steps to stem shortages of cancer treatments

'Essentially witchcraft:' A former naturopath takes on the field

knowledge

knowledge

hotspot

knowledge